NorthWest Biotherapeutics Inc (NWBO)

[md1225]

The UCLA Brain Tumor Program continues to shine as a beacon of hope, carrying a record of patients with brain tumors living longer than patients treated at any other hospital. Our personalized brain cancer vaccine, DCVax, is the first of its kind and is currently in Phase III clinical trials in 46 centers throughout America. It is on the road to FDA approval as well as clinical trials throughout Europe. Using this vaccine, we are harnessing the patient’s immune system, genetics, pathology, brain mapping and a wide database of bioinformatics to optimize outcomes.


—Neil A. Martin
Chairman and W. Eugene Stern Professor in Neurosurgery
UCLA Department of Neurosurgery